Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. 2009

Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
Novartis Institutes for Biomedical Research, Oncology Disease Area, CH-4002 Basel, Switzerland.

NVP-BEZ235 is a dual PI3K/mTOR inhibitor currently in phase I clinical trials. We profiled this compound against a panel of breast tumor cell lines to identify the patient populations that would benefit from such treatment. In this setting, NVP-BEZ235 selectively induced cell death in cell lines presenting either HER2 amplification and/or PIK3CA mutation, but not in cell lines with PTEN loss of function or KRAS mutations, for which resistance could be attributed, in part to ERK pathway activity. An in depth analysis of death markers revealed that the cell death observed upon NVP-BEZ235 treatment could be recapitulated with other PI3K inhibitors and that this event is linked to active PARP cleavage indicative of an apoptotic process. Moreover, the effect seemed to be partly independent of the caspase-9 executioner and mitochondrial activated caspases, suggesting an alternate route for apoptosis induction by PI3K inhibitors. Overall, this study will provide guidance for patient stratification for forthcoming breast cancer phase II trials for NVP-BEZ235.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011065 Poly(ADP-ribose) Polymerases Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE. ADP-Ribosyltransferase (Polymerizing),Poly ADP Ribose Polymerase,Poly(ADP-Ribose) Synthase,Poly(ADP-ribose) Polymerase,PARP Polymerase,Poly ADP Ribose Transferase,Poly ADP-Ribose Synthase,Poly(ADP-Ribose) Transferase,Poly(ADPR) Polymerase,Poly(ADPribose) Polymerase,Poly ADP Ribose Synthase,Polymerase, PARP,Synthase, Poly ADP-Ribose
D011804 Quinolines
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081082 Phosphoinositide-3 Kinase Inhibitors Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. Phosphoinositide-3 Kinase Inhibitor,Inhibitor, Phosphoinositide-3 Kinase,Inhibitors, Phosphoinositide-3 Kinase,Kinase Inhibitor, Phosphoinositide-3,Kinase Inhibitors, Phosphoinositide-3,Phosphoinositide 3 Kinase Inhibitor,Phosphoinositide 3 Kinase Inhibitors

Related Publications

Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
January 2015, Cancer cell international,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
January 2015, Clinical laboratory,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
January 2014, The Journal of urology,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
April 2020, FEBS open bio,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
August 2013, International journal of cancer,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
April 2021, Molecular medicine reports,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
October 2010, Leukemia,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
October 2008, Cancer research,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
September 2014, International journal of oncology,
Saskia M Brachmann, and Irmgard Hofmann, and Christian Schnell, and Christine Fritsch, and Susan Wee, and Heidi Lane, and Shaowen Wang, and Carlos Garcia-Echeverria, and Sauveur-Michel Maira
January 2011, PloS one,
Copied contents to your clipboard!